Psilocybin-Assisted Psychotherapy in Palliative Care
Stephen Ross, Anthony P. Bossis
Oxford University Press eBooks December 1, 2022 DOI: 10.1093/med/9780197583838.003.0042 via OpenAlex
Summary
AI-generated from the abstractMajor academic centers are resuming clinical research into psilocybin and other serotonergic psychedelics combined with psychotherapy to treat psychiatric and existential distress in terminally ill patients. Despite advances in palliative care for medical and pain symptoms, effective treatments for depression, anxiety, and demoralization at the end of life remain scarce. The World Health Organization and the Institute of Medicine have identified addressing spiritual and existential distress as essential for improving emotional well-being and quality of life in advanced illness. This chapter covers the history, anthropology, neuropharmacology, safety, and efficacy data from two waves of psychedelic research, suggesting psilocybin-assisted psychotherapy may offer a paradigm shift for improving existential, psychosocial, and spiritual well-being in palliative care.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocybin-assisted psychotherapy |
| Topics | Psilocybin |
| Keywords | Psychotherapist Palliative care Distress Existentialism |
| Key finding | Psilocybin-assisted psychotherapy may offer a paradigm shift to improve existential, psychosocial, and spiritual well-being in palliative care patients. |
Abstract
Abstract Following a decades-long hiatus and building on an innovative research model first developed from the 1960s to 1970s utilizing psychedelic therapeutics to alleviate the marked psychic distress in end-of-life cancer patients, major academic centers are resuming contemporary clinical research into the safety and efficacy of psilocybin and other serotonergic psychedelics delivered in conjunction with psychotherapeutic platforms to treat psychiatric and existential distress associated with terminal medical illnesses. While there have been significant advances in the treatment of medical and pain symptomatology in palliative care, there remains a paucity of efficacious psychopharmacologic and psychotherapeutic interventions to alleviate the psychiatric and existential anguish—notably depression, anxiety, and demoralization—often present at the end of life. Relevant to end-of-life therapeutics, the World Health Organization and the Institute of Medicine have identified treating spiritual and existential distress as essential to improving the emotional well-being and quality of life in patients with advanced or terminal illnesses. This chapter covers topics related to psilocybin-assisted psychotherapy in palliative care: history, anthropology, ethnobotany, neuropharmacology, safety, efficacy data from first and second waves of psychedelic research, putative mechanisms of action, and future directions. Psilocybin-assisted psychotherapy offers a potential paradigm shift to improve the existential, psychosocial, and spiritual well-being of patients in palliative care settings.